FORMULATION AND EVALUATION OF MONTELUKAST SODIUM AND LEVOCETIRIZINE DIHYDROCHLORIDE SUBLINGUAL TABLETS
Abstract
Â
Objective: The objective of the current study was to develop and optimize sublingual tablets of montelukast sodium and levocetirizine dihydrochloride
which are effective drugs in the treatment of asthma.
Methods: The sublingual tablets of montelukast sodium and levocetirizine dihydrochloride were prepared by direct compression method using
sodium starch glycolate, crospovidone (CP), and croscarmellose sodium (CCS) as superdisintegrants. The tablets were evaluated for physical
properties including hardness, weight variation, thickness, friability, drug content, wetting time, water absorption ratio, in vitro disintegration time,
and in vitro dissolution study.
Results: The hardness, weight variation, thickness, friability, and drug content of tablets were within pharmacopoeial limits. An optimized tablet
formulation F8 was found to have short wetting time of 18.36 seconds, water absorption ratio of 94.42 and in-vitro disintegration time of 45.42 seconds.
The results indicated that the amount of super disintegrants such as CP and CCS significantly affected the dependent variables like wetting time, water
absorption ratio and in-vitro disintegration time. The in-vitro drug release was found to be higher for formulation F8 with 94.59% for montelukast
sodium and 95.48% for levocetirizine dihydrochloride within 60 minutes. The drug release improved by 1.88 times for montelukast sodium and
1.82 times for levocetirizine dihydrochloride compared to oral marketed immediate release tablet formulation.
Conclusion: From the present study, it can be concluded that sublingual route has potential to improve the bioavailability of the drug by avoiding first
pass metabolism, to provide quicker onset of action and to improve patient compliance in the management of asthma.
Keywords: Sublingual tablet, Montelukast Sodium, Levocetirizine Dihydrochloride, In vitro dissolution study.
Downloads
References
Birudaraj R, Berner B, Shen S, Li X. Buccal permeation of buspirone: Mechanistic studies on transport pathways. J Pharm Sci 2005;94(1):70‑8.
Price TM, Blauer KL, Hansen M, Stanczyk F, Lobo R, Bates GW. Single-dose pharmacokinetics of sublingual versus oral administration of micronized 17 beta-estradiol. Obstet Gynecol 1997;89(3):340-5.
Ishikawa T, Koizumi N, Mukai B, Utoguchi N, Fujii M, Matsumoto M,et al. Pharmacokinetics of acetaminophen from rapidly disintegrating compressed tablet prepared using microcrystalline cellulose (PH-M-06) and spherical sugar granules. Chem Pharm Bull (Tokyo) 2001;49(2):230-2.
Priyanka, Pragati Kumar B. Formulation development and evaluation of montelukast sodium chewable tablets. J Chem Pharm Sci 2013;1(6):35‑40.
Saini S, Nanda A, Hooda M, Komal, Dhari J. Formulation and evaluation of mouth dissolving anti-allergic tablets of levocetirizine dihydrochloride. J Chem Pharm Res 2011;3(5):450-5.
Sangeetha S, Venkatesh DN, Krishan PN, Saraswathi R. Mucosa as a route for systemic drug delivery. Res J Pharm Biol Chem Sci 2010;1(6):178-87.
Rowe RC, Sheskey PJ, Weller PJ. Hand Book of Pharmaceutical Excipients. 4th ed. London, UK: Pharmaceutical Press; 2003. p. 108‑581.8. Basak SC, Selvin CD, Sabapathy R. Formulation and in-vitro evaluation of amoxicillin dispersible tablets. Indian Pharm 2006;5(49):71-3.
Lachman L, Lieber HA. Pharmaceutical Dosage Forms of Tablets. Vol. II. New York: Marcel Dekker; 1981. p. 241-3.
Indian Pharmacopoeia. Vol. II. Delhi: Ministry of Health and Family Welfare, Government of India; 1996. p. 350.
Chowdhary KP, Rao NR. Formulation and evaluation of dispersible tablets with pregelatinised starch. Indian Drugs 1998;35(6):368-70.
Bi Y, Sunada H, Yonezawa Y, Danjo K, Otsuka A, Iida K. Preparation and evaluation of a compressed tablet rapidly disintegrating in the oral cavity. Chem Pharm Bull (Tokyo) 1996;44(11):2121-7.
Elder EJ, Evans JC, Scherzer BD, Hitt JE, Kupperblatt GB, Saghir SA, et al. Preparation, characterization, and scale-up of ketoconazole with enhanced dissolution and bioavailability. Drug Dev Ind Pharm 2007;33(7):755-65.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.